Leap Historical Income Statement
| LPTX Stock | USD 3.30 0.14 4.43% |
Historical analysis of Leap Therapeutics income statement accounts such as Other Operating Expenses of 91.4 M can show how well Leap Therapeutics performed in making a profits. Evaluating Leap Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Leap Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Leap Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Leap Therapeutics is a good buy for the upcoming year.
Leap |
About Leap Income Statement Analysis
Leap Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Leap Therapeutics shareholders. The income statement also shows Leap investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Leap Therapeutics Income Statement Chart
Add Fundamental
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Leap Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Leap Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Leap Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Leap Stock please use our How to Invest in Leap Therapeutics guide.At this time, Leap Therapeutics' Other Operating Expenses is fairly stable compared to the past year. Research Development is likely to rise to about 76.9 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 336.9 K in 2024.
Leap Therapeutics income statement Correlations
Click cells to compare fundamentals
Leap Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Leap Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 445K | 668K | 556K | 415K | 427K | 336.9K | |
| Interest Expense | 23K | 39K | 41K | 54K | 5K | 4.8K | |
| Selling General Administrative | 9.1M | 9.6M | 10.8M | 11.8M | 13.8M | 8.7M | |
| Other Operating Expenses | 33.3M | 29.8M | 41.7M | 54.7M | 87.0M | 91.4M | |
| Operating Income | (33.5M) | (28.5M) | (41.4M) | (56.8M) | (87.0M) | (82.7M) | |
| Ebit | (33.5M) | (27.5M) | (40.6M) | (54.4M) | (81.4M) | (77.3M) | |
| Research Development | 24.4M | 20.4M | 32.2M | 45.0M | 73.2M | 76.9M | |
| Ebitda | (33.0M) | (26.8M) | (40.0M) | (54.0M) | (81.0M) | (76.9M) | |
| Total Operating Expenses | 33.3M | 29.8M | 41.7M | 54.7M | 87.0M | 91.4M | |
| Income Before Tax | (32.9M) | (27.5M) | (40.6M) | (54.4M) | (81.4M) | (77.3M) | |
| Total Other Income Expense Net | 548K | 1.0M | 815K | 2.3M | 5.6M | 5.9M | |
| Net Income | (32.9M) | (27.5M) | (40.6M) | (54.6M) | (81.4M) | (77.3M) | |
| Gross Profit | (49K) | (776K) | 1.5M | (415K) | (427K) | (405.7K) | |
| Net Income From Continuing Ops | (32.9M) | (27.5M) | (40.6M) | (54.6M) | (81.1M) | (77.0M) | |
| Cost Of Revenue | 48K | 49K | 776K | 415K | 427K | 448.4K | |
| Net Income Applicable To Common Shares | (33.3M) | (37.6M) | (40.6M) | (54.6M) | (49.1M) | (46.7M) | |
| Income Tax Expense | (3K) | (2K) | (24K) | 147K | 132.3K | 125.7K | |
| Interest Income | 313K | 93K | 9K | 925K | 3.6M | 3.8M | |
| Net Interest Income | 290K | 54K | (32K) | 871K | 3.6M | 3.8M | |
| Tax Provision | 20K | (3K) | (2K) | (24K) | 147K | 0.0 | |
| Reconciled Depreciation | 47K | 34K | 29K | 16K | 15K | 27.2K | |
| Non Operating Income Net Other | 6.4M | 126K | 738K | (379K) | (341.1K) | (324.0K) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Leap Stock Analysis
When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.